On January 15, 2026 ImmunityBio, Inc. (NASDAQ: IBRX), a vertically-integrated commercial stage biotechnology company, reported preliminary select operational results for the fiscal quarter and full year ending December 31, 2025. ImmunityBio reported preliminary net product revenue of approximately $38.3 million during the three-month period ending December 31, 2025, which represented an increase of 20% over the $31.8 million of net product revenue earned during the third quarter of 2025 and a 431% increase over the three-month period ended December 31, 2024. ImmunityBio continues to see increased sales momentum supporting a trend of increases quarter-over-quarter with a 54% quarter over quarter unit volume growth rate during FY 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company ended the quarter with an estimated $242.8 million in cash, cash equivalents and marketable securities as of December 31, 2025.

"We delivered strong quarter-over-quarter revenue growth, reflecting accelerating adoption of ANKTIVA and the continued execution of our commercial strategy," said Richard Adcock, President and CEO of ImmunityBio. "This momentum is further reinforced by the approval of ANKTIVA plus BCG in Saudi Arabia, building on existing approvals in the U.S. and U.K, as well as conditional approval in the EU."

These amounts reflect the Company’s preliminary estimates based solely upon information available to it as of the date of this press release, and the amounts reported are not a comprehensive statement of its operating results or financial position as of December 31, 2025. Any actual amounts that the Company reports in its Annual Report on Form 10-K for the year ended December 31, 2025 will be subject to its financial closing procedures and any final adjustments that may be made prior to the time its operating results and financial position for the fiscal quarter ended December 31, 2025 are finalized. As a result, these preliminary estimates may differ materially from the actual results that will be reflected in the Company’s consolidated financial statements for the fiscal year ended December 31, 2025 when they are completed and publicly disclosed in its Annual Report on Form 10-K.

"The SFDA’s landmark approval of ANKTIVA in combination with a checkpoint inhibitor for non-small cell lung cancer marks the world’s first approval of an IL-15 superagonist used in combination with checkpoint therapy," said Patrick Soon-Shiong, M.D., Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. "This approval also represents the first authorization for subcutaneous administration of ANKTIVA. Together with the continued advancement of our first-line NMIBC program, these milestones underscore the strength of our platform and position ImmunityBio for sustained growth as we work to redefine the standard of care across multiple cancers."

(Press release, ImmunityBio, JAN 15, 2026, View Source [SID1234662056])